Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates

globenewswire.com
IRON The FDA issued a Complete Response Letter for its bitopertin drug, causing a significant share price decline. The letter indicates deficiencies requiring additional data, delaying potential approval into 2027 or later. This creates a revenue gap and raises concerns about future capital raises and dilutive financing.

IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) regarding whether the company adequately communicated risks regarding its bitopertin program before the FDA’s issuance of a Complete Response Letter on February 13, 2026, which caused a 21.9% decline in share price. Investors who suffered losses on IRON stock may click here for additional information about this investigation.

The Complete Response Letter for Disc’s bitopertin indicated that the FDA required additional data before it could approve the drug for erythropoietic protoporphyria (EPP). The nature of the additional data requirements has not been fully detailed publicly, but the issuance of a CRL typically signals deficiencies in clinical efficacy data, safety concerns, or manufacturing issues that the agency considers unresolved. Each category carries different implications for the timeline and cost of a potential resubmission.

In this instance, the FDA indicated that additional results are necessary to support traditional approval. This means that Disc’s timeline for delivering bitopertin will be delayed into 2027 or potentially even further. Clinical trials in ultra-rare diseases like EPP face inherent enrollment challenges due to the small patient population, which can further extend timelines.

Disc’s pipeline beyond bitopertin includes earlier-stage programs, but none are near the regulatory stage that would offset the revenue gap created by the CRL. This raises the question of whether additional capital raises will be necessary to fund the bitopertin resubmission while maintaining other development programs. Any dilutive financing could compound losses for existing shareholders who purchased at pre-CRL prices.

Those who purchased IRON shares and want to understand their legal options may contact Levi & Korsinsky by clicking here for a free and confidential discussion.

Levi & Korsinsky, LLP is a national firm with offices in New York, Connecticut, California, and Washington, D.C. that prosecutes securities, derivative, and consumer class actions on behalf of shareholders and consumers; learn more at www.zlk.com.

CONTACT:

Joseph E. Levi, Esq.

Levi & Korsinsky, LLP

33 Whitehall Street, 27th Floor

New York, NY 10004

Tel: (212) 363-7500

Fax: (212) 363-7171

Email: jlevi@levikorsinsky.com

www.zlk.com